Immune-Mediated Hemolytic Anemia (IMHA) in Dogs and Cats

TL;DR. Immune-mediated hemolytic anemia (IMHA) is a critical, life-threatening condition where the immune system destroys its own red blood cells, requiring immediate emergency veterinary care and aggressive treatment.

IMHA is a severe, rapid-onset emergency that typically requires intensive hospitalization and supportive care.

What is it?

Immune-mediated hemolytic anemia (IMHA) is a serious disorder where the body's immune system mistakenly targets and destroys its own red blood cells. Red blood cells are responsible for carrying oxygen from the lungs to every tissue and organ in the body. When these cells are destroyed faster than the bone marrow can replace them, the pet develops moderate to severe anemia, depriving their organs of vital oxygen.

This destruction occurs through two primary pathways: extravascular and intravascular hemolysis. In extravascular hemolysis, the immune system coats the red blood cells with antibodies or complement proteins. As these flagged cells pass through the spleen and liver, specialized immune cells called macrophages recognize the flags and engulf or damage them. In intravascular hemolysis, the immune system destroys the red blood cells directly within the bloodstream, causing them to rupture and release free hemoglobin into circulation. Both pathways lead to severe tissue hypoxia (lack of oxygen), systemic inflammation, and potential organ failure.

IMHA is the most common cause of hemolytic anemia in dogs, but it is relatively uncommon in cats. Because of the rapid and aggressive nature of this disease, it is considered a true veterinary emergency. Understanding the mechanisms, recognizing the early signs, and seeking immediate veterinary intervention are critical to giving your pet the best chance of survival.

Causes & risk factors

IMHA is classified as either primary (idiopathic) or secondary. Primary IMHA occurs when the immune system malfunctions for no identifiable reason and starts attacking healthy red blood cells. This is the most common form in dogs. Secondary IMHA occurs when an underlying trigger alters the red blood cells or overstimulates the immune system, causing it to target the cells. Triggers can include:

• Infectious diseases: Vector-borne pathogens (such as Babesia, Anaplasma, or Ehrlichia in dogs, and Mycoplasma haemofelis in cats) or viral infections (like Feline Leukemia Virus in cats).
• Drugs and toxins: Certain antibiotics, anti-inflammatory medications, or exposure to toxins.
• Cancers: Lymphoma, leukemia, or other solid tumors.
• Vaccinations: In some cases, recent vaccination has been evaluated as a potential trigger, though a direct causal link is complex.

Regarding the relationship between vaccinations and IMHA, a prominent veterinary internal medicine textbook notes:

"In one study of 58 dogs with IMHA, 26% of dogs had been vaccinated within 4 weeks of developing IMHA compared with a control group in which only 5% had been vaccinated within the previous 4 weeks. (Duval et al, 1996). Mortality rates between the dogs that had been recently vaccinated and those that had not were not significantly different."

When evaluating a patient with hemolytic anemia, your vet must carefully investigate potential secondary causes, especially in certain demographics. As a leading veterinary critical care reference states:

"Hemolysis in cats, in very young or old dogs, in animals with concurrent disease or drug histories, or in animals with physical examination findings not directly related to hemolysis and anemia should prompt added vigilance for explanations other than idiopathic primary IMHA."

Signs to watch for

Symptoms of IMHA can develop suddenly or progress gradually over several days. Many of the clinical signs relate directly to the loss of oxygen-carrying red blood cells and the accumulation of waste products from their destruction.

Cardinal Sign

• Anemia: Severe reduction in red blood cell count, leading to weakness and oxygen deprivation.

Common Signs

• Pallor: Extremely pale or white gums and mucous membranes.
• Jaundice (Icterus): Yellowing of the gums, whites of the eyes, and skin, caused by a buildup of bilirubin from destroyed red blood cells.
• Depression and lethargy: Marked weakness, reluctance to move, or sleeping much more than usual.
• Exercise intolerance: Inability to perform basic physical activities without tiring rapidly.
• Thrombocytopenia: A low platelet count, which can occur concurrently with IMHA (a combination known as Evans syndrome).
• Spherocytosis: The presence of abnormally small, round red blood cells on a blood smear.
• Autoagglutination: Clumping of red blood cells.
• Polychromasia: An increased number of immature red blood cells, showing the bone marrow is trying to respond.
• Hyperbilirubinuria and Hyperbilirubinemia: Excess bilirubin in the urine and blood, causing dark orange urine and yellow tissue discoloration.
• Leukocytosis: An elevated white blood cell count due to intense systemic inflammation.

Occasional Signs

• Vomiting: Gastrointestinal upset secondary to systemic illness or hypoxia.
• Abdominal pain: Discomfort often related to liver or spleen enlargement.
• Splenomegaly: Enlargement of the spleen as it works overtime to filter out flagged red blood cells.
• Petechiae and ecchymoses: Pinpoint red spots or larger bruises on the skin or gums, indicating low platelets or clotting abnormalities.
• Hemoglobinuria and Hemoglobinemia: Free hemoglobin in the urine (making it dark red or tea-colored) and in the blood plasma.
• Heart murmur: A turbulent heart sound caused by the thin, watery consistency of severely anemic blood.
• Ghost cells: Empty outer membranes of ruptured red blood cells visible under the microscope.

Pale and yellow-tinged gums (jaundice) are classic signs of severe red blood cell destruction.

How vets diagnose it

Diagnosing IMHA requires a systematic approach to confirm that the anemia is hemolytic (due to cell destruction rather than blood loss or lack of production) and immune-mediated, while searching for any underlying triggers.

Your vet will start with a Complete Blood Count (CBC) and a blood smear evaluation. Under the microscope, the vet will look for specific hallmarks of the disease:

• Spherocytes: Red blood cells that have lost their normal donut-like shape and appear as small, dark, dense spheres. This happens when macrophages in the spleen bite off a portion of the cell membrane without fully destroying the cell.
• Ghost cells: The pale, empty shells of red blood cells that have ruptured within the blood vessels.
• Polychromasia: Variably colored, immature red blood cells (reticulocytes) indicating that the bone marrow is actively releasing new cells to combat the anemia.

Your vet will also perform a Saline Agglutination Test. This simple test mixes a drop of blood with saline on a glass slide. If antibodies are actively coating the red blood cells, the cells will clump together like microscopic bunches of grapes. A leading veterinary critical care reference explains the significance of this finding:

"True autoagglutination persists despite washing; this finding confirms an immunologic component (Figure 110-2 ). The Coombs' test is helpful when spherocytosis is minimal and autoagglutination absent to confirm the immune-mediated nature of hemolysis, as may be the case in animals with intravascular hemolysis."

If autoagglutination is not clearly visible but IMHA is still suspected, your vet may run a Direct Coombs test (also known as a direct antiglobulin test) or a Flow Cytometric Assay to detect antibodies or complement proteins bound to the surface of the red blood cells.

Additionally, a Serum Biochemistry Panel and Urinalysis are performed to assess organ function and evaluate the severity of the hemolysis. These tests often reveal elevated liver enzymes, hyperbilirubinemia (high bilirubin in the blood), and bilirubin or hemoglobin in the urine. The liver can suffer significant damage during IMHA due to a lack of oxygen. As noted in a prominent veterinary internal medicine textbook:

"Hepatic function may be compromised by hypoxia and hepatic necrosis in dogs with IMHA. In one study of 34 dogs that died of IMHA, 53% had [hepatic necrosis]."

Treatment options

Treatment for IMHA is aggressive, multi-faceted, and typically requires hospitalization in an intensive care setting.

First-Line Immunosuppressive Therapy

The cornerstone of IMHA treatment is suppressing the overactive immune system to stop the destruction of red blood cells.

• Glucocorticoids (Corticosteroids): High-dose glucocorticoid therapy (such as prednisone or injectable Dexamethasone) is initiated immediately. These medications rapidly impair the ability of macrophages to destroy flagged red blood cells.

Second-Line Immunosuppressive Therapy

If glucocorticoids alone are not successfully stopping the hemolysis, or if the side effects of steroids are too severe, your vet will add a second immunosuppressive agent. These include:

• Azathioprine: A purine antagonist immunosuppressant (used in dogs; toxic to cats).
• Chlorambucil: An immunosuppressant and antineoplastic agent often preferred for cats.
• Human Intravenous Immunoglobulin (hIVIG): An immunomodulator that can temporarily block the receptors on macrophages, preventing them from destroying antibody-coated red blood cells.

Supportive Care and Targeting Triggers

• Blood Transfusions: Severely anemic pets often require one or more transfusions of packed red blood cells or whole blood to stabilize them while the immunosuppressive drugs take effect.
• Anticoagulant Therapy: Because IMHA causes intense inflammation and platelet activation, affected pets are at an extremely high risk of developing life-threatening blood clots. Your vet will prescribe medications like ultra-low-dose aspirin, clopidogrel, or heparin to prevent clot formation.
• Antibiotics and Antiprotozoals: If a secondary infectious trigger is suspected, medications like Doxycycline, Atovaquone, or Azithromycin may be prescribed to target vector-borne pathogens.
• Splenectomy: In rare cases where medical therapy fails, removing the spleen (the primary site of red blood cell destruction) may be considered. A prominent veterinary internal medicine textbook notes:

"One retrospective case series documented a positive clinical response after splenectomy in 10 dogs with IMHA that were not responding to immunosuppressive treatment. Nine of ten dogs survived to 30 days and the hematocrit increased while transfusion requirements decreased after surgery (Horgan, 2009 )."

Prognosis

The prognosis for pets with IMHA is guarded to poor. Despite aggressive, state-of-the-art veterinary care, mortality rates remain high, ranging from 30% to 70% in various canine studies.

The most common causes of death are severe, refractory anemia that does not respond to therapy, and devastating complications like pulmonary thromboembolism (PTE)—where a blood clot travels to the lungs—and disseminated intravascular coagulation (DIC), a catastrophic failure of the body's clotting system.

For pets that survive the initial acute phase (typically the first 1 to 2 weeks), the long-term outlook improves. However, they require months of careful medication tapering, frequent blood work monitoring, and remain at risk for relapses later in life. Long-term prognosis data in cats is limited due to the rarity of the disease in this species, but feline cases also require diligent, long-term management.

Prevention

Because primary IMHA is an autoimmune disease, there is no proven way to prevent its onset. For secondary IMHA, keeping your pet on year-round flea, tick, and heartworm preventatives can significantly reduce the risk of vector-borne infections that can trigger the condition.

If your pet has survived an episode of IMHA, discuss future vaccination protocols with your vet. While vaccines are vital for preventing infectious diseases, the intense immune stimulation they cause may, in rare cases, trigger a relapse in predisposed individuals. Your vet will help you weigh the risks and benefits of future immunizations or recommend checking antibody titers instead.

When to call your vet

IMHA is a medical emergency. If you notice any of the following red flags, transport your pet to the nearest veterinary emergency hospital immediately:

• Extreme lethargy or collapse
• Pale, white, or yellow gums
• Rapid, labored, or heavy breathing
• Dark orange, red, or brown-colored urine
• Sudden weakness or inability to stand
• Unexplained bruising or pinpoint red spots on the skin or gums

For specific breeds

While IMHA can strike any dog, certain breeds have a higher suspected predisposition to developing the disease. If you own one of these breeds, be especially vigilant for the signs of anemia:

• [English Cocker Spaniel](/p/breeds/englishcockerspaniel_dog)
• English Springer Spaniel
• Golden Retriever
• Bichon Frise
• Miniature Pinscher
• Miniature Schnauzer
• Finnish Spitz
• Cocker Spaniel
• Rough Collie

Sources

• Small Animal Critical Care Medicine, 2nd Edition, pages 654–655.
• Small Animal Internal Medicine, 5th Edition, pages 1450–1453.